To study the serum level of ST-2 in COPD patient in a tertiary care center of India

Abstract

Background: In COPD patients, the abnormal inflammatory immune responses are accelerated by the IL-33/ST2 pathway activation after chronic insult from smoking, air pollution and biomass fuel exposure. Thus IL-33/ST2 act as a central driver in the pathogenesis of COPD. ST-2 is a heterodimeric receptor which in necessary for IL-33 induced downstream signal inflammatory pathway. So ST-2 receptor is a key regulator of inflammation in COPD. Aim & Objective: we aim to find out responder phenotype for anti-ST-2 therapy by the estimation of serum ST-2 levels in COPD patients in a tertiary care center of India. The objective of the present study is to assess the serum level of ST-2 in COPD patients and healthy control subjects with cigarette smoking and without cigarette smoking. Material and method: This Prospective study was done at Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun. In order to estimate serum ST2 level by ELISA method 150 COPD patients and 150 healthy control were enrolled from Shri Mahant Indresh hospital, Dehradun. Result: The concentration of ST-2 is significantly higher in COPD patients as compared to healthy control. Conclusion: It may be concluded that ST-2 may be a potential biomarkers for anti ST-2 therapies to reduce the rate of exacerbations in COPD and improve their quality of life.